Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): A trial of the eastern cooperative oncology group

Keyphrases

• Active Agent 33%
• Advanced Carcinoma 100%
• Advanced Urothelial Cancer 66%
• Advanced Urothelial Carcinoma 33%
• Chemotherapy Regimen 33%
• Confidence Interval 33%
• Docetaxel 33%
• Eastern Cooperative Oncology Group 100%
• Epothilone B 100%
• Epothilones 33%
• Fever 33%
• Granulocytopenia 66%
• Institutional Context 33%
• Ixabepilone 100%
• Median Overall Survival 33%
• Multi-institutional 33%
• Overall Response Rate 33%
• Paclitaxel 33%
• Paclitaxel-resistant 33%
• Partial Response 33%
• Phase II Trial 100%
• Previously Treated 33%
• Prior Chemotherapy 33%
• Second-line Therapy 33%
• Sensory Neuropathy 66%
• Soft Tissue 33%
• Urothelium 100%
• Visceral Tissues 33%

Medicine and Dentistry

• Carcinoma 100%
• Chemotherapy 33%
• Docetaxel 33%
• Epothilone 33%
• Epothilone B 100%
• Granulocytopenia 66%
• Isoprenaline 33%
• Ixabepilone 100%
• Oncology 100%
• Overall Survival 33%
• Paclitaxel 66%
• Patient History of Chemotherapy 33%
• Sensory Neuropathy 66%
• Side Effect 33%
• Transitional Cell Carcinoma 33%
• Urothelial Cancer 66%
• Urothelium 100%